From theheart.org on Medscape

Coverage from the

American Heart Association (AHA) Scientific Sessions 2019

November 16 - 18, 2019; Philadelphia, Pennsylvania

November 16 - 18, 2019 Philadelphia, Pennsylvania
  • AHA 2019 Silencing Novel Target Genes: A New Strategy for Lipid Lowering Following in the footsteps of inclisiran, two lipid-lowering therapies based on silencing specific genes involved in lipid metabolism showed promising preliminary results in initial clinical trials.
  • AHA 2019 DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family 'What I don't want to see is slow uptake, once it gets the indication in nondiabetics,' said one physician. Think of SGLT2 inhibitors the same way as ACE inhibitors, beta blockers, and other HF drugs.
  • AHA 2019 ISCHEMIA: PCI, Surgery Strike Out vs Meds The $100 million trial signals that not every stable patient with stable, moderate-to-severe ischemic disease needs to go to the cath lab, and will not suffer as a result.

Conference News

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

 

Bloggers From The Floor

  • Signal of Harm From Impella Has an Easy Answer Two independent observational studies find worse outcomes with the Impella device compared with intra-aortic balloon pump. The time for a randomized controlled trial is now, says John Mandrola, MD.
  • The ISCHEMIA Trial -- Cardiology Changes Today The AHA late-breaking trial comparing an invasive vs medical strategy for patients with stable ischemic disease validates Nobel prize-winning medical conservative Bernard Lown, writes John Mandrola, MD.
  • Mandrola Previews 2019 AHA and the ISCHEMIA Trial All eyes will be on ISCHEMIA in Philadelphia, but a study on asymptomatic aortic stenosis as well as trials in heart failure and cardiogenic shock also piqued Dr John Mandrola's interest.
 
 

Popular News from AHA 2018

Previous Coverage